Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

UPwArds - Post Marketing Observational Study to Evaluate the Impact of CRP-Level on the Real World Effectiveness of UPadacitinib When Used in MonotherApy or in Combination With MTX in Patients With RheumatoiD ArthritiS

Trial Profile

UPwArds - Post Marketing Observational Study to Evaluate the Impact of CRP-Level on the Real World Effectiveness of UPadacitinib When Used in MonotherApy or in Combination With MTX in Patients With RheumatoiD ArthritiS

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 11 Jul 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Methotrexate (Primary) ; Upadacitinib (Primary)
  • Indications Rheumatoid arthritis
  • Focus Therapeutic Use
  • Acronyms UPwArds
  • Sponsors AbbVie

Most Recent Events

  • 03 Jun 2023 Results effectiveness and safety after a treatment period of 12 months in three different RA patient groups: i) the total patient population, ii) patients with previous failure of TNFi (prior TNFi), and iii) patients naive to targeted-synthetic or biological disease-modifying anti-rheumatic drugs presented at the 24th Annual Congress of the European League Against Rheumatism
  • 04 Jun 2022 Interim analysis results presented at the 23rd Annual Congress of the European League Against Rheumatism
  • 10 Mar 2022 Status changed from active, no longer recruiting to completed.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top